Tag: M.W:500-600

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

To a DOTA-tra-tBu ester (28.6 mg, 0.05 mmol) in 2 mL DMF, DIPEA (24.8 mg, 0.192 mmol), HOBt (16.2 mg, 0.096 mmol), 43 (50 mg, 0.048 mmol) and EDCI (18.2 mg, 0.096 mmol) were added at 0 C. The mixture was stirred at room temperature for overnight, then 15 mL EtOAc was added to above solution. It was then washed with H20 (5 mL x 2) and brine (5 mL), dried over MgS04, and filtered. The filtrate was concentrated, and the residue was purified by FC (DCM/MeOH/NH4OH = 95/5/0.5) to give 43 as a colorless oil (yield: 26 mg, 35.6%): HRMS calcd. for C39H64N5Oio (1/2M + H)+: 762.4653, found 762.4787., 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; FIVE ELEVEN PHARMA INC.; KUNG, Hank F.; PLOESSL, Karl; CHOI, Seok Rye; ZHA, Zhihao; WU, Zehui; (131 pag.)WO2017/116994; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

170161-27-0, General procedure: The dibromide was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (39.1 mg, 78.0 mumol), KI (12.9 mg, 78.0 mumol) and K2CO3 (10.8 mg, 78.0 mumol) in CH3CN (2.50 mL) under N2 and stirred for 24 h at room temperature. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate (130 mg). A solution of the intermediate was added to bis(pyridin-2-ylmethyl)amine (12.0 mg, 60.0 mumol), KI (9.96 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at 80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate. The intermediate was then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compound 16.

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.76089-77-5,Cerium(III) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

76089-77-5, Example 4The above-described ligand represented by formula (B-10) (50 mg, 0.066 mmol) and cerium trifluoromethanesulfonate (35 mg, 0.060 mmol) were charged into a flask. Then, ethanol (4 mL) was added thereto and dissolved. The mixed solution was stirred for 2.5 hours at room temperature, and then the stirring was stopped. About 4 mL of diethyl ether was added, and the resultant mixture was left to stand overnight. After that, the produced solid was collected to obtain the above-described metal complex represented by composition formula (C-10) (hereinafter, ?metal complex (C-10)?). The collected amount was 51 mg (yield 63%).Elemental analysis: Found (%) C, 44.27; H, 4.39; N, 10.30; S, 7.33. Calcd for C50H58CeF9N10O9S3 (%) C, 44.47; H, 4.33; N, 10.37; S, 7.12.The metal complex (C-10) emitted a blue color in a solid powder state and in a solution state (acetonitrile) under ultraviolet excitation (365 nm).The emission spectrum in acetonitrile had a peak at 421 nm, the emission quantum yield was 21%, and the excitation life was 73.8 ns.

76089-77-5 Cerium(III) trifluoromethanesulfonate 2733941, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; SUMITOMO CHEMICAL COMPANY, LIMITED; US2012/211706; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

[00134] To a solution of 4-(pyren-1 -yl)butanal (37 mg, 0.14 mmol) in 0.9 ml_ DCE, Boc3Cyclam (45 mg, 0.09 mmol) was added and stirred together with 4A molecular sieves for 2 h under nitrogen atmosphere. To this solution sodium triacetoxyborohydride (38 mg, 0.18 mmol) was added and the reaction mixture was allowed to stir at ambient temperature over 24 h under nitrogen atmosphere. Subsequently, the reaction mixture was diluted with sodium bicarbonate and extracted with DCM. The extract was purified by flash chromatography with 35% ethyl acetate/hexanes to give the product (43 mg, 63%); 1 H NMR (400 MHz, CDCb) delta 8.29 (d, J = 9.3 Hz, 1H), 8.21 – 7.98 (m, 7H), 7.88 (d, J = 7.8 Hz, 1H), 3.46 – 3.09 (m, 14H), 2.59 (s, 2H), 2.50 – 2.33 (m, 4H), 1.93 – 1.74 (m, 4H), 1.73 – 1.58 (m, 4H), 1.53 – 1.41 (m, 27H); 13C NMR (100 MHz, CDCb) delta 155.69, 136.80, 131.44, 130.91, 129.80, 128.58, 127.52, 127.24, 127.20, 126.57, 125.81, 125.1 1, 125.05, 124.86, 124.81, 124.67, 123.40, 79.55, 79.36, 55.42, 48.69, 48.55, 47.30, 46.90, 46.62, 45.69, 33.54, 29.85, 29.72, 28.56, 28.50, 26.79; LRMS (ESI+) m/z calc’d for CHesN- e [M + H]+ 757.49, found 757.69., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; KRASKOUSKAYA, Dziyana; CABRAL, Aaron; MURCAR-EVANS, Bronte; TOUTAH, Krimo; DE ARAUJO, Elvin; (141 pag.)WO2019/68177; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of PKS8179 (85 mg, 188 mol) and triBoc-cyclam (94 mg, 188 mol) in DCM (4 mL)was stirred at ambient temperature for 2 h and then sodium triacetoxyborohydride (120 mg, 564 mol)was added. The resulting mixture was stirred at ambient temperature overnight. Excess reagent wasquenched with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted withdichloromethane. The combined organic layers were dried over anhydrous sodium sulfate andevaporated, and the crude residue was purified by Combi-Flash (silica gel; ethyl acetate in hexane) togive PKS8181 (140 mg, 80%) as a colorless gum which turned into a fluffy solid under vacuum., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1.2 equivalents of HATU were sequentially added to the DMF solution in which the compound 6 was dissolved at 0 C, 2 equivalents of DIPEA and 0.9 equivalents of compound 7, the reaction was naturally warmed to room temperature. After completion of the reaction, it was quenched with water and extracted with ethyl acetate. The organic phase obtained by extraction was dried over anhydrous sodium sulfate and then evaporated. The residue was purified by silica gel column chromatography to give Compound 8., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Beijing University Shenzhen Sheng Yuan; Li Zhicheng; Ye Weijian; Huang Junrong; Liang Zhenhao; (16 pag.)CN108358952; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

107-64-2, Dimethyldioctadecylammonium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5. 96 g (0.5 mol) of 3,4-dichloronitrobenzene were reacted with 26 g (0.45 mol) of potassium fluoride and 4 g of distearyldimethylammonium chloride and 4 g of tetraethylene glycol dimethyl ether at 180 C. After 4 h, the conversion was over 50% (GC) with the formation of 3-chloro-4-fluoronitrobenzene.

107-64-2, The synthetic route of 107-64-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Hoechet AG; US5545768; (1996); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI